01. Changes in proteasome ub-receptors Rpn10 and Rpn13 affect Htt degradation, Karlijne Geijtenbeek
02. Effect of small molecule inhibitors on the aggregation mechanism of Huntington Exon1, Greeshama Jain
03. Pridopidine exerts neuroprotective effects via activation of the Sigma-1 receptor, Michal Geva
04. Burn-out, Kasper van der Zwaan
05. Study update and design direction for the development of a European e-health platform for individuals with HD and their partners (HD-eHelp study), Pearl van Lonkhuizen
06. Research participation in HD: perceptions and experiences of the Dutch community, Filipa Julio
07. Efficacy and safety for tiapride for chorea treatment in HD: a systematic review, Stephanie Feleus
08. Treatment of neuropsychiatric symptoms in Huntington’s Disease: a retrospective cohort study, Ruben Andriessen
09. Pridopidine maintenance of TFC is associated with stabilization of plasma NfL levels, Michal Geva 
10. Updates from the ongoing PROOF-HD phase 3 study: PRidopidine’s Outcome On Function in Huntington Disease (PROOF), Michal Geva 
11. Identification of wild-type and mutant huntingtin interaction partners by cross-linking immunoprecipitation and LFQ-based mass spectrometry, Karen Sap